Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMISPYI)

• Drug Name: GRN-300 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMISPYI

Molecule-Related Drug Atlas

Drug(s) Targeting Salt-inducible kinase 2 (SIK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HG-9-91-01	DM8FD3Z	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting SIK family kinase 3 (SIK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HG-9-91-01	DM8FD3Z	Discovery agent	N.A.	Investigative	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Salt-inducible kinase 2 (SIK2)	TTCUGZR	SIK2_HUMAN	Inhibitor	[2]
SIK family kinase 3 (SIK3)	TTW6L4V	SIK3_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04711161) Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Green3Bio
• [3] Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91.